GO
Loading...

Enter multiple symbols separated by commas

Gilead Sciences Inc

More

  • In their June 25 lawsuit, Yale University's Global Health Justice Partnership and the Treatment Action Group, an AIDS non-profit, said doctors and patients deserve more information about the "enormously costly" drugs Harvoni and Sovaldi to make informed decisions about whether to use them. The plaintiffs said Gilead ignored its request for the trial data,...

  • June 24- AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study. All the patients in the study showed a sustained response to Viekira Pak as a standalone treatment after 12 weeks...

  • Gilead still has China patent for active compound. NEW YORK/ SHANGHAI, June 19- China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment. Gilead, however, holds the China patent to the base...

  • June 19- China has rejected Gilead Sciences Inc's application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of the drug there, a U.S. legal group announced on Friday. Gilead still has a patent in China on sofosbuvir, the main ingredient of Sovaldi, a highly effective treatment for hepatitis C which...

  • Portfolio Playbook: Buy the chips Thursday, 18 Jun 2015 | 3:23 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Portfolio Playbook: Buy the chips

  • Hedge funds top 2014 gain with these stocks Thursday, 18 Jun 2015 | 9:35 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Hedge fund returns in the first five months of the year have already surpassed the total for 2014. Here's how they're doing it.

  • NEW YORK, June 17- Tighter monetary policy typically dents a country's equity markets. "As long as inflation stays low, the sweet spot is in the equity market, particularly if the Fed is moving slowly," said Kathleen Gaffney, co-director of diversified fixed income and manager of the $1.8 billion Eaton Vance Bond Fund. Gaffney, whose fund is capped at 20 percent...

  • NEW YORK, June 17- Tighter monetary policy typically dents a country's equity markets. "As long as inflation stays low, the sweet spot is in the equity market, particularly if the Fed is moving slowly," said Kathleen Gaffney, co-director of diversified fixed income and manager of the $1.8 billion Eaton Vance Bond Fund. Gaffney, whose fund is capped at 20 percent...

  • Your drug prices too high? Here's who many blame Tuesday, 16 Jun 2015 | 3:00 AM ET
    Pharmaceuticals

    Americans place controlling drug costs at the top of their health-related concerns.

  • Cramer: Massive biotech moves that make sense Thursday, 11 Jun 2015 | 6:57 PM ET
    A worker prepares a flow cell slide for a genetic sequencing machine at a Regeneron Pharmaceuticals laboratory company's headquarters in Tarrytown, New York.

    Jim Cramer discusses the huge moves that the biotech stocks have made recently—do these moves make sense for your portfolio?

  • Which stocks seduce women vs. men Wednesday, 10 Jun 2015 | 10:03 AM ET
    Traders work on the floor of the New York Stock Exchange.

    You can see the demographic changes of stocks, as some are becoming more masculine, while others more feminine, according to data from SigFig.

  • 10 drugs to hit fed budget by $50B over decade Tuesday, 9 Jun 2015 | 1:42 PM ET
    Health Care

    Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.

  • These are the best stocks from now to October Tuesday, 2 Jun 2015 | 10:56 AM ET
    Healthcare

    Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.

  • NEW YORK, June 2- Last July, when Federal Reserve Chair Janet Yellen spurred a sell-off in healthcare stocks by saying that valuations in shares of biotech companies looked "stretched," portfolio manager Graham Tanaka saw an opportunity. After a year-long buying spree, he now has more than a quarter of his $17 million Tanaka Growth fund portfolio in healthcare...

  • Biotech investors up big amid bubble talk Thursday, 28 May 2015 | 9:56 AM ET
    Biotech

    Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.

  • *Euro rises against dollar as Greece default fears fade. *Michael Kors slumps on weak sales, weighs on rivals. *Chipmakers Broadcom, Avago surge on M&A talks.

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.

  • May 27- Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low. GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for...

  • May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. GlobeImmune is developing the drug, GS-4774, with Gilead Sciences Inc.. Companies developing hepatitis B drugs include Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals Corp and Isis...

  • GlobeImmune, Gilead Hep B drug fails in mid-stage study Wednesday, 27 May 2015 | 6:50 AM ET

    May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. However, the drug was found to reduce HBsAg, an antigen that indicates the strength of hepatitis B infection, after 48 weeks, the company said on Wednesday. GlobeImmune is developing the drug, GS-4774, with...